Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50646 | 0.79 | MAPT (0.68) | MAPTHPGDRAB9ALMNAL3MBTL1 | |
| SCHEMBL1194001 | 0.78 | TSHR (0.60) | SMN1; SMN2ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL16161046 | 0.78 | AKR1C3 (0.41) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL8045036 | 0.76 | ALDH1A1 (0.43) | ALDH1A1PDE2AAKR1C3AKR1C2 | |
| SCHEMBL16110400 | 0.76 | AKR1C3 (0.40) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL3539246 | 0.76 | PARP10 (0.48) | MAPTLMNAL3MBTL1KMT2ANOS1 | |
| SCHEMBL20560502 | 0.74 | AKR1C3 (0.39) | MAPTRAB9ALMNAKMT2AMAPK1 | |
| SCHEMBL29495930 | 0.74 | AKR1C3 (0.51) | RAB9AL3MBTL1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1195462 | 0.74 | AKR1C3 (0.51) | RAB9AL3MBTL1KMT2ASMN1; SMN2MAPK1 | |
| Benzene SCHEMBL5533098 | 0.73 | MAPT (0.75) | MAPTHPGDRAB9ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| WO-2016191935-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9079878-B2 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | PFIZER LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | PFIZER LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-8404893-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-8008352-B2 | N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | MAPT 4846/4885HPGD 2102/4885RAB9A 1114/4885 |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | MAPT 4846/4885HPGD 2102/4885RAB9A 1114/4885 |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | MAPT 3881/4885HPGD 1165/4885RAB9A 190/4885 |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | MAPT 662/4885HPGD 95/4885RAB9A 665/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAPT 332/4885HPGD 2033/4885RAB9A 1555/4885 |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | SCN8A, SCN1A, SCN5A | MAPT 2757/4885HPGD 2432/4885RAB9A 536/4885 |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSENEN | MAPT 416/4885HPGD 2512/4885RAB9A 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.